| abstract |
Powder formulation comprising 20-75 wt% of di(4-tert-butylcyclohexyl) peroxydicarbonateand 25-80 wt% of a phlegmatizer selected from the group consisting of ethylene glycol dibenzoate, phenyl benzoate, trimethylol propane tribenzoate, dimethylsulfon, ethylene glycol ditoluate, 1,3-propanediolditoluate, ethylene glycol 4-tert-butylbenzoate, ethylene glycol monobenzoate monotoluate, 2,3-butanediol dibenzoate, 4-methylphenyl benzoate acid ester, and combinations thereof. |